J. Cervantes, G. Castro, et al. Congreso ALEH. 2024.

•The aim of our study is to describe the frequency of non-alcoholic hepatic fibrosis and steatosis, as well as MASLD in patients with inflammatory bowel disease and to describe theassociated factors for these conditions.

•This is a cross-sectional and analytical study conducted from March 2023 to February 2024. The inclusion criteria were a diagnosis of IBD (ulcerative colitis or Crohn's disease) and being over 18 years old. The exclusion criteria were a diagnosis of autoimmune liver disease and risky alcohol consumption related to liver disease.
•Transient elastography (TE) with iLivTouchFT100®/UAP was performed to obtain values of steatosis and hepatic fibrosis. Additionally, the presence of metabolic syndrome criteria was evaluated to diagnose MASLD. Demographic and clinical variables of the disease were recorded. For the statistical analysis, R Commander software and the R Studio Desktop application were used.

•A total of 136 patients were included. The overall mean age was 44.83 years (SD ± 15.78), while the mean age for women was 45.35 years (SD ± 15.29).
•In the criteria for metabolic syndrome, a BMI/WC was present in 75 patients (60.98%), followed by 45 patients (38.7%) with low HDL, 33 patients (28.45%) with elevated triglycerides, 21 patients (15.4%) with some glycemic alteration, and 16 patients with hypertension.
•Regarding body fat percentage, 75 patients (62.5%) had normal values, 20 patients (16.67%) had elevated values, and 25 patients (20.83%) had low values. As for muscle percentage, 30% of the patients were within normal ranges, 63.2% had a low percentage, and only 6.72% had elevated values. Sarcopenia was present in 63 patients, representing 46.32% of the studied population.
•In UC, an analysis was conducted to determine if there were significant differences in the activity scales TLW, Mayo, Riley (remission/activity and activity levels) and the presence/absence of steatosis, as well as in CD with CDAI. No significant values (p ≥ 0.05) were observed either for the presence of activity or remission or for the levels of activity regarding the presence of hepatic steatosis.

•This study shows that in patients with inflammatory bowel disease (IBD), those with MASLD criteria have higher values for waist circumference, BMI, and body fat compared to those without hepatic steatosis or with hepatic steatosis without metabolic criteria. Disease activity was not observed to influence the presence of hepatic steatosis or MASLD. We conclude that both hepatic steatosis and MASLD are common in patients with IBD, and the associations already described for these conditions in healthy individuals are also present in patients with IBD.